ASN: Empagliflozin reduces the risk of CKD progression
WEDNESDAY, Nov. 9, 2022 (HealthDay News) — For patients with chronic kidney disease at risk of progression, the risk of kidney disease progression or cardiovascular death is reduced with empagliflozin treatment, according to a study published online November 4 in the New England Journal of Medicine to coincide with Kidney Week, the annual meeting of the American Society of Nephrology, held Nov. 3-6 in Orlando, Florida.
William G. Herrington, MBBS, MD, of the Nuffield Department of Population Health in Oxford, England, and colleagues recruited patients with chronic kidney disease with an estimated glomerular filtration rate (eGFR) of at least 20 but less than 45 mL/min/ 1.73 m2 body surface area or with an eGFR of at least 45 but less than 90 mL/min/1.73 m2 with a urinary albumin to creatinine ratio of at least 200. Patients were randomly assigned to empagliflozin or placebo (3304 and 3305, respectively).
Researchers found that during a median follow-up of 2.0 years, progression of kidney disease or death from cardiovascular causes occurred in 13.1 and 16.9% of patients in the empagliflozin and placebo, respectively (relative risk, 0.72). Among patients with or without diabetes and in subgroups defined by eGFR ranges, the results were consistent. The empagliflozin group had a lower all-cause hospitalization rate than the placebo group (hazard ratio: 0.86), but no significant difference between the groups was observed for the composite outcome of hospitalization for heart failure or cardiovascular death or death. from any cause.
“Treatment with empagliflozin resulted in a lower risk of kidney disease progression or cardiovascular death than placebo,” the authors write.
Several authors disclosed financial ties to pharmaceutical companies, including Boehringer Ingelheim and Eli Lilly, which manufacture empagliflozin and funded the study.
Abstract/Full text (subscription or payment may be required)
Copyright © 2022 Health Day. All rights reserved.